These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2148188)

  • 1. Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action.
    Schoepp DD; Ornstein PL; Leander JD; Lodge D; Salhoff CR; Zeman S; Zimmerman DM
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1301-8. PubMed ID: 2148188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonist.
    Schoepp DD; Smith CL; Lodge D; Millar JD; Leander JD; Sacaan AI; Lunn WH
    Eur J Pharmacol; 1991 Oct; 203(2):237-43. PubMed ID: 1686860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action.
    Ornstein PL; Schoepp DD; Arnold MB; Leander JD; Lodge D; Paschal JW; Elzey T
    J Med Chem; 1991 Jan; 34(1):90-7. PubMed ID: 1825117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMDA antagonist activity of (+/-)-(2SR,4RS)-4-(1H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid resides with the (-)-2R,4S-isomer.
    Ornstein PL; Schoepp DD; Arnold MB; Jones ND; Deeter JB; Lodge D; Leander JD
    J Med Chem; 1992 Aug; 35(17):3111-5. PubMed ID: 1387167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY233053: a structurally novel, potent and selective competitive N-methyl-D-aspartate receptor antagonist.
    Ornstein PL; Schoepp DD; Leander JD; Wong T; Zimmerman DM; Lodge D
    Prog Clin Biol Res; 1990; 361():429-33. PubMed ID: 2149764
    [No Abstract]   [Full Text] [Related]  

  • 6. Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes.
    Schoepp DD; Gamble AY; Salhoff CR; Johnson BG; Ornstein PL
    Eur J Pharmacol; 1990 Jul; 182(3):421-7. PubMed ID: 2171944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist.
    Lehmann J; Hutchison AJ; McPherson SE; Mondadori C; Schmutz M; Sinton CM; Tsai C; Murphy DE; Steel DJ; Williams M
    J Pharmacol Exp Ther; 1988 Jul; 246(1):65-75. PubMed ID: 2899170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo.
    Lehmann J; Schneider J; McPherson S; Murphy DE; Bernard P; Tsai C; Bennett DA; Pastor G; Steel DJ; Boehm C
    J Pharmacol Exp Ther; 1987 Mar; 240(3):737-46. PubMed ID: 2882014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist.
    Schoepp DD; Ornstein PL; Salhoff CR; Leander JD
    J Neural Transm Gen Sect; 1991; 85(2):131-43. PubMed ID: 1834088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D- aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10-imine (ADCI): comparison with the structural analogs dizocilpine (MK-801) and carbamazepine.
    Rogawski MA; Yamaguchi S; Jones SM; Rice KC; Thurkauf A; Monn JA
    J Pharmacol Exp Ther; 1991 Oct; 259(1):30-7. PubMed ID: 1920122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid.
    Schoepp DD; Lodge D; Bleakman D; Leander JD; Tizzano JP; Wright RA; Palmer AJ; Salhoff CR; Ornstein PL
    Neuropharmacology; 1995 Sep; 34(9):1159-68. PubMed ID: 8532186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of NPC 17742 [2R,4R,5S-(2-amino-4,5-(1, 2-cyclohexyl)-7-phosphonoheptanoic acid)], a potent, selective and competitive N-methyl-D-aspartate receptor antagonist.
    Ferkany JW; Hamilton GS; Patch RJ; Huang Z; Borosky SA; Bednar DL; Jones BE; Zubrowski R; Willetts J; Karbon EW
    J Pharmacol Exp Ther; 1993 Jan; 264(1):256-64. PubMed ID: 8423528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist.
    Ferkany JW; Kyle DJ; Willets J; Rzeszotarski WJ; Guzewska ME; Ellenberger SR; Jones SM; Sacaan AI; Snell LD; Borosky S
    J Pharmacol Exp Ther; 1989 Jul; 250(1):100-9. PubMed ID: 2545856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding of [3H]-CGS 19755: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain.
    Murphy DE; Hutchison AJ; Hurt SD; Williams M; Sills MA
    Br J Pharmacol; 1988 Nov; 95(3):932-8. PubMed ID: 2850065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice.
    Borowicz KK; Gasior M; Kleinrok Z; Czuczwar SJ
    Epilepsia; 1996 Jul; 37(7):618-24. PubMed ID: 8681893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.
    Krogsgaard-Larsen P; Ferkany JW; Nielsen EO; Madsen U; Ebert B; Johansen JS; Diemer NH; Bruhn T; Beattie DT; Curtis DR
    J Med Chem; 1991 Jan; 34(1):123-30. PubMed ID: 1825114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity.
    Fagg GE; Olpe HR; Pozza MF; Baud J; Steinmann M; Schmutz M; Portet C; Baumann P; Thedinga K; Bittiger H
    Br J Pharmacol; 1990 Apr; 99(4):791-7. PubMed ID: 1972895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heteroatom-substitution as a strategy for increasing the potency of competitive NMDA antagonists.
    Ornstein PL; Arnold MB; Lunn WH; Heinz LJ; Leander JD; Lodge D; Schoepp DD
    Bioorg Med Chem Lett; 1998 Feb; 8(4):389-94. PubMed ID: 9871691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
    Potschka H; Löscher W; Wlaź P; Behl B; Hofmann HP; Treiber HJ; Szabo L
    Br J Pharmacol; 1998 Nov; 125(6):1258-66. PubMed ID: 9863655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.